#Linkdoc technology plus
#Linkdoc technology series

We have developed proprietary machine learning and human language processing enabled mechanism to structure millions of clinical EMR into research grade data. We are leading oncology real world big data company from China with the vision of care data and care life.

#Linkdoc technology plus

Medical data including patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, and so on will be extracted to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer. LinkDoc Technology 892 followers on LinkedIn. The study is a real-world study and the case records of patients with advanced non-small cell lung cancer who visited the research centers from January 2014 to December 2017 and met the inclusion criteria will be collected. Independence Unified School District, KS. 1 min read (Reuters) - LinkDoc Technology Ltd, a medical data company backed by a subsidiary of Alibaba Health Information Technology Ltd, filed for an initial public.Elemene, a chemotherapeutic isolated from the Chinese medicinal herb Rhizoma Zedoariae, has been shown to have a comprehensive anti-tumor effect and the potential effect on reversing drug resistance. However, after a median of 8 to 13 months of disease control, patients ultimately progress due to acquired resistance of EGFR-TKIs. Detailed Description: This is a real-world non-interventional observational study that focuses to evaluate the effectiveness and safety of tyrosine kinase inhibitors (TKIs) in the patients of advanced non-small cell lung cancer (NSCLC) with brain metastases diagnosed by medical imaging methods. Gefitinib, Erlotinib, Icotinib, Afatinib showed efficacy superior to that of chemotherapy in the treatment of EGFR mutation positive advanced NSCLC, and lower rates of serious adverse events. LinkDoc Technology has 5 current employee profiles, including Founder Tony Zhang. It focuses on a cloud-based repository of oncology medical records. Why Should I Register and Submit Results?Ībout 9.2%-45.8% of Chinese patients with Non-small cell lung cancer were positive for EGFR gene mutation. LinkDoc Technology () is a company that offers medical data solutions and oncology big data platforms.

The Beijing-based company, which offers cancer-focused healthcare services, reported a 41 jump in revenue. The other investors in this round are not disclosed. (Reuters) - LinkDoc Technology Ltd, a medical data company backed by a subsidiary of Alibaba Health Information Technology Ltd, filed for an initial public offering in the United States on Monday. The company was established as a vehicle to diversify China’s foreign exchange holdings. LinkDoc Technology Ltd is principally engaged in providing continuous care for patients with critical diseases and data-driven precision life sciences. The pathologically diagnosed T1 NSCLC and SCLC patients who received surgeries from 2014 to 2017 were enrolled to evaluate overall survival (OS) in the total population and in the subgroups. Headquartered in Beijing, China Investment Corporation (CIC) was founded in 2007 as a wholly state-owned company, with registered capital of US$200 billion. Methods: The study was conducted based on a national collaborative lung cancer database (designed by LinkDoc Technology Co, Ltd.). Curated profile of shan he, Co-Founder / Chief Business Officer, LinkDoc Technology including career history, news and intelligence, portfolio companies and.

#Linkdoc technology series

In 2015, it also raised an undisclosed series A round from New Enterprise Associates. In 2016, the firm raised an undisclosed series B round led by China Broadband Capital, and participated by Ally Bridge Group, Cenova Capital and New Enterprise Associates. It has partnered with about 500 first-tier hospitals in more than 30 provinces and regions in China. HONG KONG, July 8 (Reuters) - Chinese medical data group LinkDoc Technology Ltd LDOC.O has shelved plans for an IPO in the United States due to Beijing's clampdown on overseas listings by.

China Investment Corporation (CIC), a sovereign wealth fund has participated in a RMB1 billion (US$151 million) series D round in Beijing-based oncology, big data firm LinkDoc Technology Ltd.įollowing in the footsteps of retail and education, healthcare firms in China have been on the VC radar and have attracted considerable funding in the recent months.įounded in 2014, the company collects and standardizes healthcare data, covering more than 3,000 diseases, from hospitals and provides customized data for healthcare regulators, researchers, insurers and pharmaceutical companies.